Lantheus (LNTH) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lantheus (LNTH) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 82.9% versus a gain of 21.8%. Over five years, LNTH leads with a +266.1% price change compared with -91.2% for NTLA. Lantheus is the larger company by market cap ($6.68 billion vs $1.40 billion), about 4.8 times the size, while Intellia Therapeutics is growing revenue faster (+16.9% vs +0.5%).
Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -609.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | NTLA |
|---|---|---|
| Share price | $102.10 | $10.00 |
| Market cap | $6.68B | $1.40B |
| 1-day change | 0.00% | +5.04% |
| YTD return | +53.42% | +11.23% |
| 1-year return | +82.91% | +21.80% |
| 5-year return | +266.08% | -91.16% |
| P/E ratio (TTM) | 25.40 | — |
| Forward P/E | 15.34 | — |
| EPS (TTM) | $4.02 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | $67.67M |
| Revenue growth (YoY) | +0.50% | +16.92% |
| Net income (latest FY) | $233.56M | $-412.69M |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | -651.67% |
| Net margin | 15.15% | -609.85% |
| 52-week high | $111.86 | $18.48 |
| 52-week low | $54.94 | $8.09 |
| Distance from 52-week high | -8.73% | -45.89% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +3.81% | +127.80% |
| Average volume | 1.02M | 5.03M |
| Shares outstanding | 65.40M | 140.36M |
| Employees | 1,193 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 4.8 times larger than Intellia Therapeutics by market value ($6.68B vs $1.40B).
- LNTH has outperformed NTLA by 61.1 percentage points over the past year.
- Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -609.9 cents for Intellia Therapeutics.
- Intellia Therapeutics grew revenue faster in its latest fiscal year (+16.92% vs +0.50%).
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
LNTH vs NTLA FAQ
Which is bigger, Lantheus or Intellia Therapeutics?
Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $1.40B for Intellia Therapeutics (NTLA).
Which stock has performed better over the past year, LNTH or NTLA?
LNTH returned +82.91% over the past 12 months, compared with +21.80% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.